Comparison of molecular abnormalities in vulvar and vaginal melanomas

Modern Pathology

Volumn 27, Issue 10, 2014, Pages 1386-1393

  Aulmann, Sebastian ^a   Sinn, Hans P ^a   Penzel, Roland ^a   Gilks, C Blake ^b   Schott, Sarah ^a   Hassel, Jessica C ^a   Schmidt, Dietmar ^c   Kommoss, Friedrich ^c   Schirmacher, Peter ^a   Kommoss, Stefan ^d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Institute of Pathology   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Melanoma; Mutation; Pathology

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLITORIS; COMPARATIVE STUDY; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DOSAGE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MIDDLE AGED; MOLECULAR PATHOLOGY; MUTATION RATE; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; ULCER; VAGINA CANCER; VERY ELDERLY; VULVA CANCER; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; VAGINA TUMOR; VULVA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 84930357188     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.211     Document Type: Article

References (20)

1. Stang A, Streller B, Eisinger B, et al. Population-based incidence rates of malignant melanoma of the vulva in Germany. Gynecol Oncol 2005;96:216-221.
2. Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, et al. Ringborg UK.Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999;86:1273-1284.
3. Tcheung WJ, Selim MA, Herndon JE II, et al. Clinicopathologic study of 85 cases of melanoma of the female genitalia. J Am Acad Dermatol 2012;76:598-605.
4. Warth A, Macher-Goeppinger S, Muley T, et al. Clonality of multifocal non-small cell lung cancer: implications for staging and therapy. Eur Respir J 2011;39:1437-1442.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
6. Penzel R, Aulmann S, Moock M, et al. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 2005;58:634-639.
7. Aulmann S, Longerich T, Schirmacher P, et al. Detection of the ASPSCR1/TFE3 gene fusion in paraffin embedded alveolar soft part sarcomas. Histopathology 2007;50:881-886.
8. Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 2004;10:3444-3447.
9. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-1901.
10. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18:3242-3249.
11. Palmieri G, Casula M, Sini MC, et al. Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med 2007;11:1052-1068.
12. Van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149:883-893.
13. Hocker T, Taso H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutation 2007;28:578-588.
14. Sekine S, Nakanishi Y, Ogawa R, et al. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Arch 2009;454:513-517.
15. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-256.
16. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-4346.
17. Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008;99:2065-2069.
18. Omholt K, Grafström E, Kanter-Lewensohn L, et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011;17:3933-3942.
19. Alexis JB, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and resulst of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res 2005;15:283-285.
20. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-2909.